Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16372362 | 0.82 | RIPK1 (0.41) | TAAR1IDO1MAOBRIPK1 | |
| SCHEMBL172686 | 0.82 | TAAR1 (0.45) | TAAR1IDO1AOC3ALDH1A1MAOB | |
| SCHEMBL125583 | 0.82 | ALDH1A1 (0.49) | TAAR1IDO1ALDH1A1MAOBMAPK1 | |
| SCHEMBL15066239 | 0.80 | TAAR1 (0.47) | TAAR1IDO1AOC3ALDH1A1MAOB | |
| SCHEMBL7005775 | 0.79 | TAAR1 (0.52) | TAAR1IDO1AOC3ALDH1A1MAOB | |
| SCHEMBL15257739 | 0.79 | TAAR1 (0.42) | TAAR1IDO1AOC3ALDH1A1MAOB | |
| SCHEMBL28738485 | 0.79 | TAAR1 (0.42) | TAAR1IDO1AOC3ALDH1A1MAOB | |
| SCHEMBL28203033 | 0.79 | CES2 (0.43) | TAAR1IDO1AOC3ALDH1A1MAOB | |
| SCHEMBL7955109 | 0.77 | TAAR1 (0.56) | TAAR1IDO1AOC3ALDH1A1MAOB | |
| SCHEMBL2962884 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249639-A1 | Use of 9H-Purine-2,6-Diamine Derivatives in the Treatment of Proliferative Diseases and Novel 9H-Purine-2,6-Diamine Derivatives | BAENTELI ROLF | 2007-10-25 | — | — | US | claimed |
| EP-1734968-A2 | USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES | Novartis AG (CH) | 2006-12-27 | — | — | EP | claimed |
| WO-2005097135-A2 | USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | claimed |
| EP-2595985-A1 | ISOXAZOLE, ISOTHIAZOLE, FURANE AND THIOPHENE COMPOUNDS AS MICROBICIDES | Syngenta Participations AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| EP-2595984-A1 | MICROBICIDES | Syngenta Participations AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010568-A1 | MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012010567-A1 | ISOXAZOLE, ISOTHIAZOLE, FURANE AND THIOPHENE COMPOUNDS AS MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-26 | — | — | WO | disclosed |
| US-20070249639-A1 | Use of 9H-Purine-2,6-Diamine Derivatives in the Treatment of Proliferative Diseases and Novel 9H-Purine-2,6-Diamine Derivatives | BAENTELI ROLF | 2007-10-25 | — | — | US | disclosed |
| CN-1972929-A | Heterocyclic CGRP antagonists for the treatment of migraine | BRISTOL MYERS SQUIBB CO (US) | 2007-05-30 | — | — | CN | disclosed |
| EP-1734968-A2 | USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES | Novartis AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097135-A2 | USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | disclosed |
| US-5272268-A | Dipeptide derivatives | SHIONOGI & CO., LTD. (JP) | 1993-12-21 | — | — | US | disclosed |
| US-5223615-A | Hypotensive agents | SHIONOGI & CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5194608-A | Hypotensive agents; inhibits renin-angiotensin system | SHIONOGI & CO., LTD. (JP) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249639-A1 | Use of 9H-Purine-2,6-Diamine Derivatives in the Treatment of Proliferative Diseases and Novel 9H-Purine-2,6-Diamine Derivatives | HPRT1, NUDT1, DPYD | TAAR1 1714/4885IDO1 1764/4885AOC3 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.